Home » Newsletters » BioWorld Science

BioWorld Science

March 5, 2018

View Archived Issues

Biogen and AbbVie voluntarily withdraw Zinbryta worldwide

Ethics committee approves phase I study of cancer vaccine BIL-06v

Researchers present phase I data for norovirus vaccine VXA-G1.1-NN

Novel human insulin analogues created at Jiangsu Hengrui Medicine

Dosing begins in first in human trial of CPX-POM in patients with advanced solid tumors

AureoGen Biosciences descibes new aureobasidin A derivatives

Merck KGaA divulges novel BTK inhibitors

Novel muscarinic acetylcholine M4 receptor PAMs patented by Vanderbilt University

Marine compound conjugated to trastuzumab is active against HER2+ tumors

Moogene Medi describes DPP4-targeting cas9 protein and guide RNAs

FDA accepts NDA for Jazz Pharmaceuticals' solriamfetol

Gene therapy from Meiragtx receives European PRIME disgnation

CARB-X supports Macrolide's development of macrolide antibiotics with Gram-negative activity

Santhera reports findings from phase I/II trial of idebenone in primary progressive MS

FDA approves Otonomy's Otiprio for acute otitis externa

New phase I trial explores use of HB002.1M in neovascular AMD

CYP11A1 expression identifies anaphylaxis risk in children with peanut allergy

HEC Pharm's HBV capsid inhibitor HEC-72702 shows promise for further development

DCIR found as potential therapeutic target for atopic dermatitis

Idera initiates phase III study of IMO-2125 with ipilimumab for refractory melanoma

Max Planck Gesellschaft and Arsanis Biosciences synthesize antibodies targeting K. pneumoniae LPS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...